Zevra Therapeutics Statistics Share Statistics Zevra Therapeutics has 56.14M
shares outstanding. The number of shares has increased by 5.17%
in one year.
Shares Outstanding 56.14M Shares Change (YoY) 5.17% Shares Change (QoQ) 2.66% Owned by Institutions (%) 65.53% Shares Floating 55.45M Failed to Deliver (FTD) Shares 5,609 FTD / Avg. Volume 0.32%
Short Selling Information The latest short interest is 7.4M, so 13.18% of the outstanding
shares have been sold short.
Short Interest 7.4M Short % of Shares Out 13.18% Short % of Float 13.26% Short Ratio (days to cover) 5.65
Valuation Ratios The PE ratio is -3.66 and the forward
PE ratio is 17.15.
Zevra Therapeutics's PEG ratio is
-0.05.
PE Ratio -3.66 Forward PE 17.15 PS Ratio 16.34 Forward PS 3.4 PB Ratio 9.72 P/FCF Ratio -5.54 PEG Ratio -0.05
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Zevra Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 2.53,
with a Debt / Equity ratio of 1.52.
Current Ratio 2.53 Quick Ratio 2.47 Debt / Equity 1.52 Debt / EBITDA -0.79 Debt / FCF -0.87 Interest Coverage -11.84
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $400.2K Profits Per Employee $-1.79M Employee Count 59 Asset Turnover 0.13 Inventory Turnover 3.76
Taxes Income Tax 15.37M Effective Tax Rate -17.05%
Stock Price Statistics The stock price has increased by 29.67% in the
last 52 weeks. The beta is 1.5, so Zevra Therapeutics's
price volatility has been higher than the market average.
Beta 1.5 52-Week Price Change 29.67% 50-Day Moving Average 9.52 200-Day Moving Average 8.71 Relative Strength Index (RSI) 55.65 Average Volume (20 Days) 1,773,417
Income Statement In the last 12 months, Zevra Therapeutics had revenue of 23.61M
and earned -105.51M
in profits. Earnings per share was -2.28.
Revenue 23.61M Gross Profit 16.2M Operating Income -87M Net Income -105.51M EBITDA -76.4M EBIT -82.79M Earnings Per Share (EPS) -2.28
Full Income Statement Balance Sheet The company has 33.78M in cash and 60.3M in
debt, giving a net cash position of -26.51M.
Cash & Cash Equivalents 33.78M Total Debt 60.3M Net Cash -26.51M Retained Earnings -505.29M Total Assets 256.28M Working Capital 197.5M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -69.67M
and capital expenditures 0, giving a free cash flow of -69.67M.
Operating Cash Flow -69.67M Capital Expenditures n/a Free Cash Flow -69.67M FCF Per Share -1.51
Full Cash Flow Statement Margins Gross margin is 68.59%, with operating and profit margins of -368.47% and -446.85%.
Gross Margin 68.59% Operating Margin -368.47% Pretax Margin -381.76% Profit Margin -446.85% EBITDA Margin -323.56% EBIT Margin -368.47% FCF Margin -295.04%
Dividends & Yields ZVRA does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast The average price target for ZVRA is $23.5,
which is 152.4% higher than the current price. The consensus rating is "Buy".
Price Target $23.5 Price Target Difference 152.4% Analyst Consensus Buy Analyst Count 6
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Dec 28, 2020. It was a
backward
split with a ratio of 1:16.
Last Split Date Dec 28, 2020 Split Type backward Split Ratio 1:16
Scores Altman Z-Score -0.81 Piotroski F-Score 5
